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esponsibility of InstAbstract A simple and effective high-performance liquid chromatography with diode-array detection
method coupled with a liquid-liquid extraction pretreatment has been developed for determining the
pharmacokinetics and tissue distribution of a novel structurally modiﬁed derivative (8-acetamino-
isocorydine) of isocorydine. According to the in vivo experiments data calculations by DAS 2.0 software,
a two-compartment metabolic model was suitable for describing the pharmacokinetic of 8-acetamino-
isocorydine in rats. 8-Acetamino-isocorydine was absorbed well after oral administration, and the absolute
bioavailability was 76.5%. The half-life of 8-acetamino-isocorydine after intravenous and oral adminis-
tration was 2.2 h and 2.0 h, respectively. In vivo, 8-acetamino-isocorydine was highly distributed in the
lungs, kidney and liver; however, relatively little entered the brain, suggesting that 8-acetamino-
isocorydine could not easily pass through the blood brain barrier. Our work describes the ﬁrst
characterization of the pharmacokinetic parameters and tissue distribution of 8-acetamino-isocorydine.2
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Pharmacokinetics study on 8-acetamino-isocorydine 239The acquired data will provide useful information for the in vivo pharmacology of 8-acetamino-
isocorydine, and can be applied to new drug research.
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and isocorydine (ICD).1. Introduction
Aporphine alkaloids belong to benzylisoquinoline alkaloids, existing in
20 families and more than 100 genera of plants, including Magnolia-
ceae, Menispermaceae, Euphorbiaceae, Lauraceae, Loganiaceae,
Annonaceae, Aristolochiaceae, Berberidaceae, Papaveraceae, Ranun-
culaceae, Rutaceae, etc. These alkaloids share the common characte-
ristic of a tetracyclic skeleton, albeit with different substituents. The
aporphine template is associated with a wide range of biological
activities, such as antioxidant, anti-platelet aggregation, anticonvulsant,
anticancer antimalarial, antiprotozoal, antipoliovirus, cytotoxic and anti-
Parkinson's disease. Because of their attractive biological activities,
many studies have focused on the potential of aporphinoid alkaloids in
drug development, and the anticancer activity of these compounds has
become a hot pharmaceutical research area in recent years1–6.
Isocorydine (ICD), an aporphine alkaloid, is widely present in
many plants, including Dicranostigma leptopodum (Maxim) Fedde,
which mainly distributed in the northwest of China7,8. ICD was
reported many biological activities, for example, the spasmolytic,
antiplasmodial, antiarrhythmic, analgesic activity and vasodilative
activity9,10. In 2003, ICD hydrochloride was authorized by China
State Food and Drug Administration (SFDA) to be commercialized
(Chinese Drug Approval No. H53021977). It was listed as both a
prescription drug and a medicare drug to cure diverse endogenous
pain. Previous studies demonstrated that ICD prohibited the proli-
feration of hepatocellular carcinoma cell lines both in vitro and in vivo
by inducing G2/M cell cycle arrest. In addition, ICD treatment led to a
decrease of the percentage of CD133þ PLC/PRF/5 cells. Furthermore,
ICD treatment dramatically decreased the tumorigenicity of SMMC-
7721 and Huh7 cells. These ﬁndings indicate that ICD might be a
potential therapeutic drug for the chemotherapeutic treatment of
hepatocellular carcinoma11,12. However, the short half-life, rapid
elimination, and low tolerated dose (LD50¼32.2 mg/kg in mice13)
present limitations to its development as a novel chemotherapy14–15.
In order to improve the anti-cancer activity, increase the tolerated
dose, and extend half-life of ICD, we modiﬁed the structure of ICD to
obtain a series of derivatives. After screening research, we found that
8-amino-isocorydine possesses the better anti-cancer activity than
isocorydine. 8-Amino-isocorydine is synthesized by introducing
amino in C-8 site of isocorydine parent structure. But 8-amino-
isocorydine is not stable in aqueous solution at room temperature.
Even the weak oxidant sodium nitrite could oxidize 8-amino-
isocorydine to 6a,7-dihydrogen-isocorydione, because the p-amino-
phenol segment in the structure of 8-amino-isocorydine could be
easily oxidized in aqueous solution under the presence of hydrogen
ion. To achieve the stabilized active compounds, based on the pro-
drug theory, 8-acetamino-isocorydine (AICD, structure shown in
Fig. 1) was synthesized through acetylating 8-amino-isocorydine with
acetyl chlorine. The pharmacological experiments showed AICD has a
good inhibitory effect on murine hepatoma H22-induced tumors. The
inhibitory rate of H22 tumor was 52.71% after a dose 200 mg/kg/d of
oral administration16. Thus, we selected AICD as a candidate for newdrug development. The results suggested that the structural modiﬁca-
tions of isocorydine at C-8 could signiﬁcantly improve the biological
activity of this alkaloid, indicating its suitability as a lead compound in
the development of an effective anticancer agent16,17.
In order to obtain more information on AICD in vivo, it is necessary
to determine its pharmacokinetic properties and tissue distribution. A
variety of methods have been used to study the pharmacokinetics of
ICD, including high-performance liquid chromatography coupled with
ultraviolet detection (HPLC-UV)18,19 and high-performance liquid
chromatography–electrospray ionization–tandem mass spectrometry
(LC-ESI-MS/MS)20,21. However, the use of high-performance liquid
chromatography with diode-array detection (HPLC-DAD) is ideal for
analyzing ICD in a biological matrix because it is simple, economical,
applicable, and provides an acceptable sensitivity and stability. Thus,
we used HPLC-DAD to analyze the plasma and tissue homogenates
after oral and intravenous administration of AICD in rats. The results
showed that AICD enhanced the tolerated dosage and moderately
extended the half-life as compared with ICD, which implied that the
dosage and the drug delivery time should be adjusted during the new
drug research and the pharmacological investigation in vivo
about AICD.2. Materials and methods
2.1. Chemicals and reagents
D. leptopodum (Maxim) was picked from Pingliang, Gansu, China. It
was identiﬁed by Professor Zhigang Ma (College of Basic Medical
Science, Lanzhou University). The reference compound of ICD, used
as the internal standard (IS), was extracted, isolated, and puriﬁed from
D. leptopodum by repeated column chromatography and recrystalliza-
tion. ICD was identiﬁed by Nuclear Magnetic Resonance spectrum and
compared with the literature. AICD was synthesized in our laboratory.
The purity of AICD and ICD was both more than 98%, as determined
by HPLC-DAD analysis, based on the peak area normalization
method. Methanol purchased from J&K Chemicals (USA) was of
chromatographic grade. Analytical grade dichloromethane, diethylether,
ethyl acetate, and ammonia were purchased from Rionlon Tianjin
Yali Chen et al.240Chemical Co., Ltd. (Tianjin, China). Distilled and deionized water was
used for the preparation of samples and solutions.
2.2. Instrumentation
An Agilent 1200 series liquid chromatography system (Agilent
Technologies, Palo Alto, USA), equipped with a G1312A binary
pump, a G1315B diode array detector performing wavelength
scanning from 190 nm to 950 nm, a G1328B manual injector, and
Agilent Chemstation software (version A.10.02) was used. The
chromatographic separation of the analytes was performed on a
SinoChrom ODS-BP C18 analytical column (250 mm 4.6 mm,
5 μm, Dalian Elite Analytical Instruments Co., Dalian, China) at
30 1C. Data analysis was performed on DAS 2.0 software (Drug
and Statistics, Mathematical Pharmacology Professional Commit-
tee of China). An XK96-A Vortex Mixer (Xinkang Instrument
Co., Ltd., Jiangsu, China) and TGL-16G Desk Centrifuge (Anting
Instrument Co., Ltd., Shanghai, China) were used.
2.3. Animals
Wistar rats (male, 200–220 g) were obtained from the Animal
Center of Gansu University of Traditional Chinese Medicine,
Gansu, China (License No. SCXK (Gan) 2004-0006). Animals
were bred in a breeding room with a temperature of 25 1C, relative
humidity of 50%710%, and a 12 h dark-light cycle. All of the
animals had free access to water and rodent chow at all times, and
all of the experimental animals were fed under the above
conditions for one week. The night before experiments, the access
to food was limited. Research was conducted in accordance with
all institutional guidelines and ethics, and was approved by the
Laboratories Institutional Animal Care and Use committee of the
Gansu University of Traditional Chinese Medicine.
2.4. Preparation of standard solutions and quality control (QC)
samples
A stock solution of AICD was prepared in methanol with a ﬁnal
concentration of 1.0 mg/mL. A series of standard solutions with
concentration of 0.1, 0.5, 5.0, 15.0, 40.0, 120.0, 360.0 and
1100.0 μg/mL were obtained by further dilution of the stock solution
with methanol. The standard solution of the IS was diluted with
methanol to a concentration of 100.0 μg/mL. All the solutions were
kept at 20 1C, and brought to room temperature before use.
To prepare a series of standard calibration samples, 10 μL of the
standard solution at different concentrations were evaporated to
dryness by a gentle stream of nitrogen, and 100 μL of the drug-free
rat plasma or tissues homogenates was added. The mixture was then
processed by a sample extraction procedure, which is described in
Section 2.5. The ﬁnal standard plasma and tissues concentrations
were 0.01, 0.05, 0.5, 1.5, 4.0, 12.0, 36.0, and 110.0 μg/mL. QC
samples with no IS were prepared as same as standard calibration
solutions. QC samples containing AICD in plasma had concentrations
of 0.5, 5.0, 50.0 and 100.0 μg/mL (very low, low, middle and high,
respectively). All of these solutions were prepared fresh before use.
2.5. Sample pretreatment
In this study, a conventional liquid-liquid extraction (LLE) method was
used to extract the AICD from biological samples (plasma, tissue
homogenates). Biological samples were thawed at room temperature,and a 100 μL plasma sample was spiked with 10 μL IS standard
solution (100 μg/mL). After brieﬂy mixing, 400 μL of dichloromethane
was added and mixed by vortex for 1 min. The sample was centrifuged
at 10,000 rpm for 10 min at room temperature. The subnatant was
collected and evaporated to dryness under a gentle stream of nitrogen at
room temperature. The residue was reconstituted with 100 μL of the
mobile phase, and 20 μL was injected to the HPLC system.
2.6. Chromatographic conditions
The mobile phase consisted of methanol with 0.02% aqueous ammonia
(pH 7.3, 70:30, v/v) with a ﬂow rate of 1 mL/min. Isocratic elution was
used for all processes. The analytic column was a SinoChrom ODS-BP
C18 (250 mm 4.6 mm, 5 μm). Chromatograms were monitored at
270 nm and the temperature of column was kept at 30 1C.
2.7. Method validation
All methods used on biological samples were validated following
the guidelines of the US Food and Drug Administration (FDA)22.
The validation parameters included selectivity, linearity, accuracy,
precision, recovery and stability.
Selectivity was evaluated by comparing 6 individual blank
plasma and spiked plasma samples. The purpose of this assay was
to detect the level of interference in blank plasma at the retention
time of the AICD and IS.
Calibration curves were obtained by linear regression of the peak
area ratio of AICD to IS (Y-axis) and the standard concentration (0.01,
0.05, 0.5, 1.5, 4.0, 12.0, 36.0 and 110.0 μg/mL), which constituted the
range of the calibration curve (X-axis). The calibration line was
corrected by a weighted factor (1/X2), described as Y¼aþbX. Each
QC sample was recalculated using the calibration curve. Acceptable
values were permitted to differ from the nominal value by715%, with
the exception of the lower limit of quantiﬁcation (LLOQ), which was
permitted to differ by 720%. The limit of detection (LOD) was
determined as the lowest concentration of AICD in the biological
samples that corresponds to 3 times of the baseline noise (S/N¼3).
The LLOQ was deﬁned as the lowest concentration of AICD in plasma
which caused a signal to noise ratio of 10 (S/N¼10). The analyte
concentration in the calibration curve of the LLOQ should be
quantitatively determined with an acceptable precision of o20%.
Accuracy and precision were calculated using the QC samples.
Five replicates of each sample were injected on three consecutive
days, and the concentration was back calculated from the values
on the calibration curve. The accuracy was expressed with a
relative error (RE) and the precision was expressed as the relative
standard deviation (RSD). The acceptable range of both the RE
and RSD was 15%, while LLOQ did not exceed 20%.
The recovery of AICD was performed by comparing the peak
area of the added AICD in plasma or tissue homogenates with the
same amount of AICD added to the mobile phase. Four concen-
trations of QC samples (0.5, 5.0, 50.0 and 100.0 μg/mL) were
evaluated in the recovery experiments (n¼5 for each QC).
The stability of the sample was evaluated in different storage
conditions. The amount of AICD in rat plasma was determined
using the QC samples under the following 4 storage conditions: (1)
after three freeze-thaw cycles (20 1C/room temperature) with a
freezing time of at least 12 h, followed by measurement of the
change in the sample; (2) after the sample was maintained at room
temperature for 4 h, followed by measurement of the change in the
sample; (3) after the sample was maintained at 20 1C (storage
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the sample; and (4) after the sample was maintained in centrifuge
tubes at room temperature for 24 h, followed by measurement of
the change in the sample. All of these QC samples were prepared
fresh, and the acceptable range of stability was less than 15%
(n¼5 for each QC).
2.8. Pharmacokinetical assay of AICD
Wistar rats (n¼12, male) were randomly divided into two equal
groups. One group was administrated AICD (100 mg/kg, i.v.)
through the tail vein, whereas the other group was administered
oral AICD (200 mg/kg) (the doses data were studied by the activity
experiment16). The dose formulation of AICD was prepared in 0.9%
sterile saline to contain 20 mg/mL or 40 mg/mL of AICD for i.v. or
oral administration, respectively. All rats were fasted 12 h before
administration. Rats were bled from the retro-orbital sinus by
capillary tubes at the following time points: 0 (pre-dose), 0.033,
0.083, 0.25, 0.5, 0.83, 1.33, 2, 3, 4, 6 and 8 h for i.v. administration
and 0 (pre-dose), 0.033, 0.083, 0.25, 0.5, 0.83, 1.33, 2, 3, 4, 6, 8, 10
and 12 h for oral administration. Each blood sample (300 μL) was
collected in heparinized tubes and centrifuged at 4000 rpm for
15 min to obtain the plasma. The separated plasma was frozen at
20 1C before the assay.
2.9. Tissue distributed assay of AICD
Rats (n¼24) were randomly divided into four equal groups, and each
rat was administrated AICD (100 mg/kg) through the tail vein. The
four groups of rats were euthanized 10 min, 1 h, 3 h or 6 h after
administration. Dissected organs and tissues included the heart, liver,
brain, lungs and kidneys from each rat. The organs were cleaned with
physiological saline, which was absorbed by ﬁlter paper. The tissues
were then weighed and homogenized in normal saline solution
(250 mg/mL), and the obtained tissue homogenates were stored at
20 1C until analysis.
2.10. Calculations
All data was calculated using Microsoft Excel 2007 (Microsoft Co.,
USA) and OriginPro 8.0 (OriginLab Co., USA) software. The
concentration-time curves and pharmacokinetic parameters of AICD
were obtained through the DAS 2.0 software (Shanghai, China).3. Results
3.1. Optimization of HPLC conditions
Methanol with 0.02% aqueous ammonia (pH 7.3, 70:30, v/v) was used
as mobile phase and the analytic column was a SinoChrom ODS-BP
C18 column (250 mm 4.6 mm, 5 μm); chromatograms were mon-
itored at 270 nm and isocratic elution was used for all processes.
Reverse phase (RP)–HPLC is the main tool used for the analysis of
alkaloids. However, alkaloids can interact with free silanol groups on
the surface of the silica particles which cause the chromatogram tailing
in RP chromatography. For this reason, two new generation columns
Waters XTerra MS C18 (250 mm 4.6 mm, 5 μm) and SinoChrom
ODS-BP C18 (250 mm 4.6 mm, 5 μm) were selected for our
experiments. These columns can be endcapped to decrease the number
of surface silanols and ensure low silanol activity, thereby improvingthe ability to separate alkaloids. The pH value of the mobile phase was
the most important factor in the RP-HPLC separation of alkaloid
compounds, because the retention behavior of alkaloids can be greatly
affected by the pH of the mobile phase. The alkaloids tend to easily
gain a proton and become ionized in acidic conditions, because they
are generally basic and nucleophilic compounds that have one or two
nitrogen atoms. Thus, the retention behavior of alkaloids in an RP-
column is strongly dependent on the composition of mobile phase. The
retention time of aporphine alkaloids was increased due to decreases in
their polarity as pH values increased. In contrast, some aporphine
alkaloids were converted into their protonated form under acidic
conditions, resulting in decreased retention time on C18 column.
Generally, the pKa values of aporphine alkaloids are 7.10–7.16
(ICD, 7.16)23, and introducing a methyl group at nitrogen atom often
results in the formation of a strong base. Thus, adjusting the pH value
of mobile phase above 7.16 may be useful to resolve the tailing
observed in AICD and ICD. Triethylamine or ammonia aqueous
solution was therefore added to the mobile phase in order to compete
with those free silanol groups on the surface of the silica and overcome
the peak broadening and tailing. The XTerra MS C18 column is more
suitable when applied under the acidic mobile phase, unlike the
SinoChrom ODS-BP C18 column. Thus, we selected the SinoChrom
ODS-BP C18 column for our experiment. AICD was prepared by
chemical modiﬁcation of ICD and two compounds that possess the
same basic chemical skeleton. As a result, ICD was selected as the IS
in order to reduce error.
To improve the peak shape, acetonitrile and methanol were
selected as the organic phase of mobile phase, and triethylamine
and aqueous ammonia were selected as the additive for the
aqueous phase. AICD and ICD have better solubility in methanol
than acetonitrile, and the best chromatographic peak shape of the
analyte was observed using a methanol and aqueous ammonia
solution as the mobile phase. Overall, methanol with 0.02%
aqueous ammonia (pH¼7.3, 70:30, v/v) and a ﬂow rate at
1 mL/min obtained the best peak shape, appropriate retention time
(AICD at 4.0 min and ICD at 6.8 min), and good resolution. Thus,
this mixture was selected as the mobile phase for the next
pharmacokinetic and tissue distributional analysis.
3.2. Optimization of the sample preparation
Protein precipitation and LLE were used for the pretreatment of
biological samples, but the results showed that protein precipitation
was not suitable to extract AICD and ICD (IS) from biological
samples, due to their low recovery and the interference of biological
samples. Several extraction solvents were explored for LLE, such as
dichloromethane, ethyl ether, ethyl acetate, and dichloromethane, and
were shown to be superior to others in their high recovery of analytes.
Further, the extracted samples were relatively purity and had few
impurities in the chromatographic peaks or interference peaks. Based
on the low number of impurity peaks, low background noise and rapid
evaporation, we chose dichloromethane as the best extraction solvent
for AICD and ICD (IS). Thus, the LLE method and dichloromethane
were ﬁnally chosen for the biological sample preparation.
3.3. Validation of the HPLC assay
Selectivity of the method was evaluated by comparing the blank
plasma and spiked plasma. Representative chromatograms of the
blank plasma, blank plasma spiked with AICD and IS, and the real
plasma are shown in Fig. 2. Tissue homogenates results are shown
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the retention time of AICD and IS in the blank plasma and tissue
homogenates. This suggested that there was no endogenous
interference of the AICD and IS in plasma and tissues.
The calibration curves for AICD were obtained by extraction of
the blank plasma or ﬁve tissue homogenates (heart, liver, brain,
lungs and kidneys). AICD in all matrices exhibited excellent
linearity (all correlation coefﬁcients exceeded 0.9900) over the
linear ranges. Thus, all quantitative calculations used the results
obtained from the blank plasma as the standard equation for the
next investigation. Between 0.05 μg/mL and 110 μg/mL, the cali-
bration curves exhibited a very good linear relationship. The linear
equation is Y¼0.101X 0.091 and the correlation coefﬁcient was
r¼0.9985. The LLOQ (n¼5, S/N¼10) and LOD (n¼5, S/N¼3)
of AICD in rat plasma were 0.10 μg/mL and 0.05 μg/mL, whereas
in liver homogenates they were 0.18 μg/ml and 0.10 μg/mL. The
linearity and selectivity were suitable for the study of pharmacoki-
netic and tissue distribution.
The accuracy was represented by the RE of QC samples, RE (%)
¼ (CdetCnom)/Cnom 100, where Cnom was calculated from the
nominal concentration and Cdet was the mean value of the detected
concentration. Precision was demonstrated as the RSD, using the
formula, RSD (%)¼ (standard deviation (SD))/Cdet 100. The
data of intra-day and inter-day accuracy and precision of AICD
are shown in Table 1. As the data shows, the intra-accuracy ranged
from 1.5% to 8.9%, and the inter-accuracy ranged from 2.8%
to 6.9%. Additionally, the intra-precision ranged from 8.6% to
10.7% and the inter-precision ranged from 4.3% to 10.9%. The
experimental results for intra-day and inter-day accuracy and
precision were within the acceptable limits.
The extraction recovery of AICD was determined by four QC (0.5,
5.0, 50.0 and 100.0 μg/mL) concentration samples. In both rat plasma
and biological samples, the extraction recovery was greater than
78.8%. All the data are shown in Table 1. The data suggest that
dichloromethane suitably recovers AICD in a biological matrix.Figure 2 Representative chromatograms for the pharmacokinetic
investigation of AICD: (a) blank plasma sample; (b) standard solution
in blank plasma including AICD and IS (ICD); (c) real plasma sample
processed 50 min after oral administration of AICD (200 mg/kg); (d)
real plasma sample processed 50 min after i.v. administration of AICD
(100 mg/kg). Mobile phase: methanol with 0.02% aqueous ammonia
adjusted to pH 7.3 (70:30, v/v) with a ﬂow rate of 1 mL/min; column:
SinoChrom ODS-BP C18 (250 mm 4.6 mm, i.d. 5 μm); detection
wavelength: 270 nm; retention time: AICD at 4.0 min and ICD at
6.8 min.The stability data are shown in Table 2. The samples were
stable when kept at room temperature for 4 h, after three freeze-
thaw cycles, and after long-term placement for 40 d and 24 h in a
room temperature environment. The results suggest that AICD
undergoes negligible degradation under these circumstances.
Thus, the method of sample storage at 20 1C was feasible
and suitable for further pharmacokinetic and tissue distribution
studies.
3.4. Pharmacokinetics
The pharmacokinetic proﬁles were determined from a rat plasma
concentration-time course after oral or i.v. administration of AICD.
The mean concentration-time curves in rats receiving i.v. AICD
(100 mg/kg) and oral AICD (200 mg/kg) are shown in Fig. 3. The
plasma concentration of AICD decreased rapidly within the initial
2 h after i.v. administration, and then gradually decreased to the
LLOQ during the next 6 h. In contrast, following oral administra-
tion of AICD, the concentration increased quickly, and reached the
maximum plasma concentration (Cmax) at 0.8 h after administra-
tion. The plasma concentration then decreased to the LLOQ by
12 h.
According to the pharmacokinetic calculations by DAS 2.0
software, which is the authoritative software for the pharmacoki-
netic calculations, a two-compartment model of in vivo metabo-
lism best ﬁt the data on AICD in rats. The pharmacokinetic
parameters after i.v. and oral administration are shown in Table 3.
The absolute bioavailability (F) was calculated as 76.5% using the
formula: F (%)¼ (AUC0–1,oralDosei.v.)/(AUC0–1,i.v.Doseoral)
 10024–26, based on the AUC0–1 obtained after i.v. and oral
administration. The half-life of AICD after i.v. and oral adminis-
tration was 2.2 h and 2.0 h, respectively, both of which were
longer than the half-life of ICD reported in the literature (24.910
for i.v. and 28.915 min for oral, or 1.21 h for i.v. and 0.906 h for
oral)14,15.
3.5. Tissue distribution
Tissue distribution was performed at 10 min, 1 h, 3 h, and 6 h
after i.v. administration at a single dosage at 100 mg/kg. Repre-
sentative chromatograms for organs and tissues in rats are shown
in Fig. S1A–E, and the statistics results are shown in Fig. 4. The
lungs, kidneys and liver homogenate had high concentration of
AICD at the four time points, suggesting that AICD easily enters
these organs. In contrast, low levels of AICD were observed in the
brain, suggesting that it may not cross the blood brain barrier
(BBB). These data suggest that AICD may be effective in the
treatment of liver, lung and kidney cancers.4. Discussion
Modiﬁcations at the C-8 position in the D ring of isocorydine were
the focus of our screening antitumor agents16. The hydrogen atom
located at C-8 possesses high chemical reactivity and is easily lost.
So 8-amino-isocorydine has been obtained which was proved to
have a good antitumor effect in vitro but was not stable in aqueous
solution. So, under the pro-drug theory, AICD was synthesized
through acetylating 8-amino-isocorydine with acetyl chlorine,
which could not only protect the p-aminophenol segment, but
could also be hydrolyzed by enzymolysis and transform to the
original compound in vivo. These investigations about their
Table 1 The intra-day and inter-day precision, accuracy and recovery of AICD in rat plasma and biological matrix (n¼5).
Sample
matrix
QC
concentration
(μg/mL)
Intra-day Inter-day Recovery
(mean7SD, %)
Accuracy
(mean %)
Precision
(mean %)
Accuracy
(mean %)
Precision
(mean %)
Plasma 0.5 2.5 2.6 1.6 4.3 101.273.1
5 8.9 2.9 6.1 1.8 88.073.9
50 7.4 1.2 3.2 3.3 86.471.1
100 5.3 1.7 3.5 3.6 84.372.5
Heart 0.5 2.8 0.3 3.9 1.4 88.972.1
5 1.7 4.6 3.8 7.6 81.271.4
50 2.6 3.0 6.4 10.9 80.571.0
100 2.1 2.3 3.0 7.1 79.873.1
Liver 0.5 2.8 8.6 5.3 3.0 86.175.8
5 0.7 4.0 4.9 6.5 84.971.6
50 0.2 1.7 5.9 0.6 82.571.3
100 1.2 3.5 4.4 3.2 80.772.8
Brain 0.5 2.5 7.6 4.4 2.0 96.272.5
5 3.3 3.6 3.6 4.5 86.471.9
50 2.6 1.6 2.0 3.2 84.171.3
100 1.5 3.7 2.8 5.1 82.673.2
Lung 0.5 2.5 9.1 6.9 6.0 88.973.1
5 1.5 10.7 2.6 9.0 82.371.7
50 5.0 9.8 2.7 2.9 80.471.5
100 4.7 8.9 3.0 3.6 78.971.4
Kidney 0.5 1.7 8.2 6.5 4.3 88.371.2
5 0.1 4.8 2.4 2.3 82.971.8
50 2.1 2.9 0.8 2.0 80.671.2
100 2.3 2.5 1.6 3.2 78.871.7
Table 2 Stability of AICD in rat plasma (n¼5).
Sample
matrix
QC concentration
(μg/mL)
Freeze and thaw stability
(mean7SD, %)
Short-term stability
(mean7SD, %)
Long-term stability
(mean7SD, %)
Post-preparative stability
(mean7SD, %)
Plasma 0.5 104.173.5 100.773.2 95.473.2 121.473.2
5 99.571.6 102.273.4 92.0710.4 103.873.1
50 104.876.6 101.874.1 92.979.5 91.971.1
100 102.574.2 100.973.7 96.875.6 93.673.1
Heart 0.5 104.172.9 95.872.6 87.572.4 100.172.8
5 110.571.9 89.071.5 99.471.7 110.672.0
50 108.272.9 89.472.3 94.072.5 91.572.4
100 105.473.8 93.772.8 97.373.6 95.473.2
Liver 0.5 102.274.7 89.773.2 108.273.8 110.774.2
5 101.170.7 103.770.7 88.270.6 99.470.7
50 99.670.2 92.470.2 87.570.2 92.770.2
100 102.671.5 93.771.9 90.373.2 95.771.4
Brain 0.5 101.672.9 115.072.8 110.072.7 100.075.0
5 101.274.0 96.373.3 88.573.0 92.173.1
50 100.772.6 92.872.4 86.672.2 96.372.0
100 99.373.0 93.472.7 90.173.5 95.372.3
Lung 0.5 103.872.6 106.772.7 89.572.2 92.472.3
5 99.971.6 92.471.4 90.971.4 86.671.3
50 103.575.3 101.175.2 89.174.5 92.374.7
100 98.574.2 94.673.9 90.274.1 93.573.8
Kidney 0.5 101.271.9 98.571.7 100.271.7 90.671.6
5 95.371.1 100.171.2 86.771.0 87.171.0
50 93.072.0 91.772.0 88.471.9 91.571.9
100 97.172.2 93.972.7 90.672.1 92.372.4
Pharmacokinetics study on 8-acetamino-isocorydine 243anticancer activities in vitro and in vivo suggested that structural
modiﬁcations could signiﬁcantly improve the anticancer activity of
ICD alkaloid and have lower side effects on body weight.The result of the pharmacokinetics and tissue distribution
investigation about the AICD supported that t1/2 of AICD in rats
after i.v. and oral administration were 2.2 h and 2.0 h, respectively.
Figure 3 Plasma concentration-time proﬁles of AICD in rats by oral
administration (200 mg/kg) and i.v. administration (100 mg/kg).
Table 3 Main pharmacokinetic parameters of AICD after
oral administration (200 mg/kg) and i.v. administrations
(100 mg/kg) (n¼6). MRT: mean retention time, CLz/F and
Vz/F are statistical moment parameters; CL/F and V/F are
clearance and volume of distribution through bioavailability
calibration; Zeta means the tail section slope of the concentra-
tion-time curve.
Oral i.v.
Parameter Mean7SD Parameter Mean7SD
A 76.932753.879 A 20.12271.414
α 2.97471.984 α 11.22776.780
B 13.05773.805 B 22.08873.674
β 0.20170.042 β 0.73670.210
AUC0–t
(mg/Lh)
57.44376.912 AUC0–t
(mg/Lh)
36.19574.986
AUC0–1
(mg/Lh)
59.34278.377 AUC0–1
(mg/Lh)
38.77077.954
MRT0–t (h) 3.69770.195 MRT0–t (h) 1.62770.399
MRT0–1 (h) 4.04570.458 MRT0–1 (h) 2.22471.095
t1/2z (h) 2.00370.615 t1/2z (h) 2.24671.005
Tmax (h) 0.83070.000 CLz (L/h/kg) 2.66070.532
CLz/F
(L/h/kg)
3.42070.467 Vz (L/kg) 8.05871.974
Vz/F (L/kg) 9.59771.582 Zeta 0.35970.158
Zeta 0.36770.092
Cmax (μg/L) 14.09372.067
F (%) 76.50070.500
Figure 4 Statistical results of the tissue distribution of AICD in rats
after i.v. administration (100 mg/kg).
Yali Chen et al.244We suppose the main reason of this phenomenon was that AICD
could eliminate fast in intestinal, thus AICD in rats after oral
administration can eliminate faster than after i.v. administration.
However, the chemical structure modiﬁcation indeed changed the
metabolic behavior of ICD, and the result of pharmacokinetics and
tissue distribution study about the AICD indicated that AICD
remained in rats for a relatively long time. This implied that AICD
could have fast and long-lasting pharmacological effects in vivo,
which would be more effective than ICD. According to the tissue
distribution data, we found that AICD did not pass through the
BBB, unlike its parent compound ICD15, mainly because introdu-
cing an acetamino in the D-ring C-8 site of ICD enhanced itspolarity and hydrophilicity. The tissue distribution results sug-
gested that the adverse reactions in the central nervous system
(such as nausea, vomiting, drowsiness and dizziness) might be
reduced when using AICD. Compared with ICD, we found that
AICD had a relatively longer effect period, a higher bioavailability
and a higher tolerated concentration, suggesting it may be an ideal
anti-cancer drug.
During the compartment model simulation of AICD, we found
that two-compartment metabolic model was suitable for describing
the pharmacokinetic of AICD in rats. In two-compartment model,
AICD entered blood-rich tissues and organs (such as heart, liver,
kidney, etc.) ﬁrst, and then AICD distributed into the peripheral
compartment (such as skin, muscles, nerves, etc.). This metabolic
approach indicated that a large amount of AICD can reach the
target organs quickly. Therefore, AICD could play a long-lasting
and effective role in therapeutic hepatocellular carcinoma or lung
and kidney cancer. Of course, the investigation about metabolic
pathways, metabolites and other pharmacokinetic parameters
should be carried out for full understanding the disposition of
AICD in vivo. Meanwhile, the protective group that has more
space volume such as benzoyl group should be applied to extend
the half-life of AICD.
The pharmacological activity and pharmacokinetic studies of
AICD by our group supported that the structural modiﬁcation of
natural products is an essential method for the new drugs
development. The chemical modiﬁcation would provide the basis
to explore the structure-activity relationship about the targeted
compound.5. Conclusions
A simple and effective HPLC-DAD method coupled with an LLE
method was developed for determining the metabolic behavior and
tissue distribution of AICD. AICD can be quickly absorbed and
eliminated, and its Tmax and t1/2 were 0.8 h and 2.0 h, respectively,
after oral administration. AICD was absorbed well after oral
administration, and its absolute bioavailability was 76.5%. For
the ﬁrst time, the pharmacokinetic and tissue distributional
parameters of this isocorydine derivative were reported, which
will provide more useful information for AICD in vivo pharma-
cological investigation and the new drug research.
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